{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:35:00Z","timestamp":1787495700635,"version":"build-2736575974"},"reference-count":40,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:p>Biologic medications are essential for treating chronic diseases but come with high costs, prompting interest in biosimilars as more affordable alternatives. Biosimilars are highly similar to FDA-approved biologics in terms of safety and efficacy, though not identical. Managed Care Organizations (MCOs), especially those contracted by Medicaid in New York, play a key role in formulary management and cost containment. Despite over 600 approved biologics, only approximately 69 biosimilars are available, and their adoption varies widely. This study evaluates cost and clinical outcomes across three disease states\u2014Rheumatoid Arthritis (RA), Crohn\u2019s Disease (CD), and Type 1 Diabetes Mellitus (DM)\u2014using biologic-biosimilar pairs: Adalimumab (Cyltezo), Infliximab (Avsola), and Insulin Glargine (Semglee). We aim to understand pricing discrepancies and the lag in biosimilar uptake within MCO formularies through cost-effectiveness analysis. Findings will inform whether clinical equivalence translates into formulary preference and support efficient resource allocation while maintaining patient access and treatment outcomes. A formulary review identified high-cost biologics with FDA-approved biosimilars used in managed care. RA, CD, and T1DM were selected based on prevalence and cost impact. Biologics included Humira, Remicade, and Lantus, with biosimilars Cyltezo, Avsola, and Semglee. Selection was based on FDA approval, formulary access, and clinical relevance. Efficacy and safety were confirmed through trial review and real-world data. Cost-effectiveness was assessed using ICER, calculated from annual treatment costs and clinical outcomes, with a $50,000 willingness-to-pay threshold. Biosimilars demonstrated strong cost-effectiveness compared to their reference biologics. Cyltezo showed better clinical response than Humira (69% vs 64.5%) at a much lower annual cost ($6600 vs $107,992.82), yielding an ICER of \u2013$2.25 million. Avsola was also more effective than Remicade (68.1% vs 59.1%) and significantly cheaper ($24,000 vs $50,500), with an ICER of \u2013$297,752.81. Semglee and Lantus had equivalent outcomes, but Semglee cost less ($1775.76 vs $4896), supporting a cost-minimization approach. Despite favorable outcomes, biosimilars were often placed on equal or higher formulary tiers than reference biologics due to rebate contracts, limited interchangeability, and provider hesitancy. Biosimilars offer equal or better clinical outcomes at much lower costs in RA, CD, and T1DM. Cyltezo and Avsola were dominant in both efficacy and cost, yet their formulary placement remains inconsistent due to rebate-driven incentives, provider hesitancy, and administrative barriers. To improve adoption, MCOs and PBMs should prioritize value-based formulary decisions, enhance transparency, and support provider and patient education. Pharmacists can help lead biosimilar use through counseling and substitution protocols. Greater alignment between clinical evidence and formulary practices can lower costs, improve access, and promote sustainable care.<\/jats:p>","DOI":"10.1177\/08971900251394782","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T23:20:22Z","timestamp":1762212022000},"page":"373-380","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Value of Biosimilars: A Cost-Effectiveness Approach for Managed Care Organizations"],"prefix":"10.1177","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7352-2514","authenticated-orcid":false,"given":"Vishwanauth","family":"Persaud","sequence":"first","affiliation":[{"name":"Touro College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reanne","family":"Bernstein","sequence":"additional","affiliation":[{"name":"Touro College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wertheimer","sequence":"additional","affiliation":[{"name":"Touro College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"e_1_3_3_2_2","unstructured":"Medicaid. Managed care. medicaid.gov. 2022. https:\/\/www.medicaid.gov\/medicaid\/managed-care. Accessed April 2 2025."},{"key":"e_1_3_3_3_2","unstructured":"NYC.gov. Medicaid - ochia. https:\/\/www.nyc.gov\/site\/ochia\/coverage-care\/medicaid.page. Accessed April 4 2025."},{"key":"e_1_3_3_4_2","volume-title":"Medicaid Enrollment: Getting the Facts Straight","author":"Kinnucan M","year":"2025","unstructured":"Kinnucan M. Medicaid Enrollment: Getting the Facts Straight. Fiscal Policy Institute. Published February 15, 2025. Accessed April 4, 2025. https:\/\/fiscalpolicy.org\/medicaid-enrollment-getting-the-facts-straight"},{"key":"e_1_3_3_5_2","volume-title":"Biosimilar Review and Approval","author":"U.S. Food and Drug Administration","unstructured":"U.S. Food and Drug Administration. Biosimilar Review and Approval. FDA. https:\/\/www.fda.gov\/drugs\/biosimilars\/review-and-approval. Accessed April 11, 2025."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph1702023"},{"key":"e_1_3_3_7_2","unstructured":"U.S. Food and Drug Administration. FDA at a glance. Published April 2023. https:\/\/www.fda.gov\/media\/168049\/download. Accessed April 11 2025."},{"key":"e_1_3_3_8_2","volume-title":"Biosimilar Product Information","author":"U.S. Food and Drug Administration","unstructured":"U.S. Food and Drug Administration. Biosimilar Product Information. FDA. https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information. Accessed April 11, 2025."},{"key":"e_1_3_3_9_2","volume-title":"Federal Barriers Make Biologic Drugs Unaffordable","author":"Katebi C","unstructured":"Katebi C. Federal Barriers Make Biologic Drugs Unaffordable. America First Policy Institute. Published November 29, 2023. https:\/\/americafirstpolicy.com\/issues\/federal-barriers-make-biologic-drugs-unaffordable. Accessed April 11, 2025."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2024.30.2.206"},{"key":"e_1_3_3_11_2","volume-title":"New biosimilars continue to be approved but uptake varies by class","author":"Myshko D","unstructured":"Myshko D. New biosimilars continue to be approved but uptake varies by class. Manag Healthc Exec. Published May 23, 2024. https:\/\/www.managedhealthcareexecutive.com\/view\/new-biosimilars-continue-to-be-approved-but-uptake-varies-by-class. Accessed April 11, 2025."},{"key":"e_1_3_3_12_2","unstructured":"National institute of arthritis and musculoskeletal and skin diseases. Rheumatoid arthritis. National institute of arthritis and musculoskeletal and skin diseases. Published November 2022. https:\/\/www.niams.nih.gov\/health-topics\/rheumatoid-arthritis. Accessed April 11 2025."},{"key":"e_1_3_3_13_2","unstructured":"Pfizer. Rheumatoid arthritis. https:\/\/www.pfizer.com\/disease-and-conditions\/rheumatoid-arthritis. Accessed April 11 2025."},{"key":"e_1_3_3_14_2","unstructured":"Ellis CR Azmat CE. Adalimumab. PubMed. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557889\/"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212245"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.07.003"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01944-y"},{"key":"e_1_3_3_19_2","volume-title":"Totality of Evidence. AVSOLA HCP","author":"Avsola (infliximab-axxq)","unstructured":"Avsola (infliximab-axxq). Totality of Evidence. AVSOLA HCP. Amgen Inc. https:\/\/www.avsola.com\/hcp\/totality-of-evidence. Accessed August 6, 2025."},{"key":"e_1_3_3_20_2","unstructured":"Cleveland Clinic. Type 1 diabetes. Published January 2024. https:\/\/my.clevelandclinic.org\/health\/diseases\/21500-type-1-diabetes. Accessed April 11 2025."},{"key":"e_1_3_3_21_2","volume-title":"National Diabetes Statistics Report","author":"Centers for Disease Control and Prevention","year":"2024","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. CDC; 2024. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html. Accessed April 11, 2025."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13322"},{"key":"e_1_3_3_23_2","volume-title":"Effectiveness and safety","author":"Boehringer Ingelheim","unstructured":"Boehringer Ingelheim. Effectiveness and safety. Cyltezo\u00ae (adalimumab-adbm). https:\/\/patient.boehringer-ingelheim.com\/us\/products\/cyltezo\/about-cyltezo\/effectiveness-and-safety. Accessed April 13, 2025."},{"key":"e_1_3_3_24_2","volume-title":"Multi-Discipline Review: BLA 761086 \u2013 Avsola (infliximab-axxq)","author":"U.S. Food and Drug Administration","unstructured":"U.S. Food and Drug Administration. Multi-Discipline Review: BLA 761086 \u2013 Avsola (infliximab-axxq). Center for Drug Evaluation and Research. Published August 14, 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761086Orig1s000MultidisciplineR.pdf. Accessed April 13, 2025."},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2337\/cd22-0016"},{"key":"e_1_3_3_26_2","volume-title":"Lexi-Drugs Online","year":"2025","unstructured":"Lexicomp. Insulin glargine-yfgn. In: Lexi-Drugs Online. Wolters Kluwer Health; 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/320047. Accessed April 13, 2025."},{"key":"e_1_3_3_27_2","volume-title":"Lexi-Drugs Online","year":"2025","unstructured":"Lexicomp. Lantus (insulin glargine). In: Lexi-Drugs Online. Wolters Kluwer Health; 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/320047. Accessed April 13, 2025."},{"key":"e_1_3_3_28_2","volume-title":"Lexi-Drugs Online","year":"2025","unstructured":"Lexicomp. Infliximab-axxq. In: Lexi-Drugs Online. Wolters Kluwer Health; 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7084. Accessed April 13, 2025."},{"key":"e_1_3_3_29_2","volume-title":"Lexi-Drugs Online","year":"2025","unstructured":"Lexicomp. Remicade (Infliximab). In: Lexi-Drugs Online. Wolters Kluwer Health; 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/7084. Accessed April 13, 2025."},{"key":"e_1_3_3_30_2","volume-title":"Lexi-Drugs Online","year":"2025","unstructured":"Lexicomp. Adalimumab-adbm. In: Lexi-Drugs Online. Wolters Kluwer Health; 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/6285. Accessed April 13, 2025."},{"key":"e_1_3_3_31_2","volume-title":"Lexi-Drugs Online","year":"2025","unstructured":"Humira (Adalimumab). In: Lexi-Drugs Online. Wolters Kluwer Health; 2025. https:\/\/online.lexi.com\/lco\/action\/doc\/retrieve\/docid\/patch_f\/6285. Accessed April 13, 2025."},{"key":"e_1_3_3_32_2","unstructured":"U.S. Department of Veterans Affairs. VA formulary advisor. https:\/\/www.va.gov\/formularyadvisor\/. Accessed April 13 2025."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2022.89188"},{"key":"e_1_3_3_34_2","unstructured":"Jeremias S. Survey shows payers more likely to prefer multiple biosimilars for the same reference product. Am J Manag Care. 2023. https:\/\/www.ajmc.com\/view\/survey-shows-payers-more-likely-to-prefer-multiple-biosimilars-for-the-same-reference-product. Accessed April 13 2025."},{"issue":"2","key":"e_1_3_3_35_2","first-page":"54","article-title":"Biosimilars: considerations for payers","volume":"44","author":"Smeeding J","year":"2019","unstructured":"Smeeding J, Malone DC, Ramchandani M, Stolshek B, Green L, Schneider P. Biosimilars: considerations for payers. P T. 2019;44(2):54-63.","journal-title":"P T"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0546"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2019.25.1.102"},{"key":"e_1_3_3_38_2","volume-title":"Realizing the Benefits of Biosimilars: Overcoming Rebate Walls","author":"Arad N","year":"2022","unstructured":"Arad N, Staton E, Hamilton Lopez M, et al. Realizing the Benefits of Biosimilars: Overcoming Rebate Walls. Duke-Margolis Center for Health Policy; 2022. https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2022-03\/Biosimilars\/20-\/20Overcoming\/20Rebate\/20Walls.pdf. Accessed April 13, 2025."},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-021-00509-3"},{"key":"e_1_3_3_40_2","unstructured":"Jeremias S. Experts pressure congress to remove roadblocks for biosimilars. Center for biosimilars. Published April 12 2025. https:\/\/www.centerforbiosimilars.com\/view\/experts-pressure-congress-to-remove-roadblocks-for-biosimilars. Accessed April 13 2025."},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.7249\/rhq-07-04-03"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251394782","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08971900251394782","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08971900251394782","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:18:51Z","timestamp":1787494731000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08971900251394782"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1177\/08971900251394782"],"URL":"https:\/\/doi.org\/10.1177\/08971900251394782","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]}}}